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Abstract 
Xanthorrhizol (XNT) is a bisabolane-type sesquiterpenoid compound extracted from Curcuma xanthorrhiza Roxb. It 
has been well established to possess a variety of biological activities such as anticancer, antimicrobial, anti-inflam-
matory, antioxidant, antihyperglycemic, antihypertensive, antiplatelet, nephroprotective, hepatoprotective, estro-
genic and anti-estrogenic effects. Since many synthetic drugs possess toxic side effects and are unable to support 
the increasing prevalence of disease, there is significant interest in developing natural product as new therapeutics. 
XNT is a very potent natural bioactive compound that could fulfil the current need for new drug discovery. Despite 
its importance, a comprehensive review of XNT’s pharmacological activities has not been published in the scientific 
literature to date. Here, the present review aims to summarize the available information in this area, focus on its anti-
cancer properties and indicate the current status of the research. This helps to facilitate the understanding of XNT’s 
pharmacological role in drug discovery, thus suggesting areas where further research is required.
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Background
Natural products are always characterized as more 
drug-likely and biological friendly than totally synthetic 
molecules [1]. Many of them have been proven to have 
better compatibility with biological system and lesser 
side effects. New chemical entities derived from natural 
products have played a key role in many drug discovery 
programmes including anticancer, antimicrobials and 
anti-inflammatory drugs. They are considered as good 
lead compounds suitable for further modification dur-
ing drug development. The World Health Organisation 
(WHO) estimated that annual global use of herbal medi-
cines is about US $83 billion in 2008, indicating that nat-
ural products are important sources of new therapeutics 
and future medicines [2].
Studies of Lahlou addressed that alternative drug dis-
covery methods for synthetic drugs failed to deliver many 
lead compounds in medicinal therapy [1]. It has been 
proven that many synthetic drugs have limited poten-
tial due to toxic side effects and treatment inefficiency. 
For instance, failure in chemotherapy is caused by dose-
limiting toxicity related to drug resistance [3]. Since drug 
resistance is caused by human multidrug resistance asso-
ciated proteins (MRPs) [4], natural product such as XNT 
may contribute new therapeutics that could suppress 
MRPs, thus improving current medication use.
To date, no comprehensive review has been done 
on the pharmacological activities of XNT. The present 
review aims to summarize the available information in 
this area, focus on its anticancer properties and indicate 
the current status of the research. This helps to facilitate 
the understanding of XNT’s pharmacological role in drug 
discovery, thus suggesting areas where further research is 
required.
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Discovery of xanthorrhizol (XNT)
XNT is the most active and abundant compound isolated 
from the essential oil of the rhizomes of Curcuma xan-
thorrhizza Roxb. [5], also known as Java turmeric [6]. C. 
xanthorrhiza (Fig.  1) is a ginger-like plant of the family 
Zingiberaceae [7, 8], which is distributed in Southeast 
Asia region [8, 9]. Although it originates from Indonesia 
[7], it has been grown wild and cultivated in Thailand, 
Philippines, Sri Lanka and Malaysia [10]. It has a round 
tuber [7] with the dingy yellow outer skin (Fig. 2) and yel-
low flesh [11]. The rhizomes smell balmy and taste bitter 
[11].
There are several methods used to extract the essential 
oil and XNT including supercritical fluid carbon diox-
ide extraction (SCFE-CO2), Soxhlet extraction and per-
colation process [8]. According to Salea and colleagues 
(2014), SCFE-CO2 at factor combination of pressure 
15 MPa, temperature 50 °C, flow rate 15 g/min and dura-
tion 60  min, has the highest XNT compared to Soxhlet 
and percolation extraction system. Before the introduc-
tion of SCFE-CO2, many researchers [6, 12–20] were still 
using conventional solvent extraction method to isolate 
XNT. Since the cost production of using SCFE-CO2 is 
much higher than conventional method, we suggest that 
SCFE-CO2 is more applicable in large-scale production 
in the industry.
Conventionally, the dried rhizomes of C. xanthorrhiza 
are grounded and soaked in 95  % ethanol for 2  days at 
room temperature [6]. The filtrate is subjected to a rotary 
evaporator to produce a concentrated extract under 
reduced pressure. Next, it is separated by silica gel col-
umn chromatography eluted with n-hexane–ethyl acetate 
solution (10:1, v/v) to give different fractions. The desired 
fraction is further purified by reverse phase (C18) column 
chromatography and eluted with 80  % methanol. The 
presence of XNT in each fraction is pre-identified using 
thin layer chromatography (TLC) [14, 18]. Then, high 
performance liquid chromatography (HPLC) analysis 
(≥98  %) [21] and gas chromatography–mass spectrom-
etry (GC–MS) [14, 18] are used to determine the purity 
of XNT. Finally, succeed isolation of XNT is confirmed 
by NMR spectral analysis [14, 18]. It is categorized as a 
bisabolane-type sesquiterpenoid compound [7, 10]. The 
structure of XNT is shown in Fig. 2.
Historical application of XNT
Previous studies evaluated that XNT has antimicrobial 
[15, 16, 19, 22–25], anti-inflammatory [10, 17, 26, 27], 
antioxidant [5, 17], antihyperglycemic [6], antihyper-
tensive [21, 28], antiplatelet [29], nephroprotective and 
hepatoprotective [30–32], estrogenic and antiestrogenic 
properties [20, 33]. These pharmacological activities are 
summarized in Table 1.
Antimicrobial properties
XNT is considered active against a variety of pathogenic 
microorganisms. Antimicrobial effects of XNT included 
antibacterial [15, 16, 22], anticandidal [19, 23] and anti-
fungal activities [24, 25]. There have been evaluated 
by in  vitro susceptibility tests such as minimum inhibi-
tory concentration (MIC), minimum bactericidal con-
centration (MBC), minimum fungicidal concentration 
(MFC), NCCLS (M38-A) standard method and biofilm 
quantification.
Earlier study by Hwang and colleagues reported that 
XNT showed the highest antibacterial activity against 
dental caries causing bacteria (Streptococcus species) 
followed by periodontitis causing bacteria (Actinomy-
ces viscosus and Porphyromona gingialis) [16]. XNT also 
strongly inhibited Gram-positive bacteria Staphylococ-
cus aureus, methicillin-resistant Staphylococcus aureus 
(MRSA), Gram-negative bacteria Escherichia coli [34] 
and acne-causing bacteria Propionibacterium acnes [35].
Moreover, the ability of XNT in preventing dental 
plaque and removing oral bacterial biofilms has been 
demonstrated on the oral Streptococcus mutans biofilms 
in vitro [22]. Biofilms removal activities were affected by 
XNT concentration, exposure time and the biofilm phase 
growth. For example, XNT (5 µM) completely inhibited 
Fig. 1 C. xanthorrhiza Roxb. It is a ginger-like plant of the family 
Zingiberaceae. The flowers are generally yellow, where the sheath is 
yellow and the aerial part is purple
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Fig. 2 Isolation of XNT from the rhizome of C. xanthorrhiza Roxb. Purity of XNT is determined by GC–MS at 100 % abundance. XNT is then identified 
by NMR spectral, which is characterized as a bisabolane-type sesquiterpenoid compound
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the formation of S. mutans biofilms at adherent growth 
phase, whilst XNT (50 µM) removed 76 % of biofilm at 
plateau accumulated phase after 60 min exposure. XNT 
killed S. mutans at planktonic growth due to its direct 
contact with biofilm outer layer cells [15, 22, 36]. The 
antimicrobial activities were induced by the capability of 
the hydrophobic chains of XNT to penetrate and reduce 
the viability of dental plaque biofilm [37].
For anticandidal activity, XNT inhibited planktonic 
cells of Candida albicans at MICs range of 1–15 µg/mL 
[19]. This finding is controversial with the previous result 
[16], where Candida albicans were found to be resistant 
to XNT. Since there is lack of information on the XNT’s 
condition used in the previous work [16], we infer that 
XNT dissolved in dimethyl sulfoxide (DMSO) [19] may 
enhance anticandidal activity towards C. albicans. The 
ability of XNT to prevent and kill C. albicans was further 
supported by Rukayadi and Hwang, where XNT at 8 µg/
mL completely reduced C. albicans biofilms at adherent 
phase, whilst 32 µg/mL reduced 88 and 67.5 % of biofilm 
at intermediate and mature phase, respectively [23]. It 
was also active against pathogenic non-Candida albicans 
species such as C. glabrata, C. guilliermondii and C. par-
apsilosis biofilms in vitro [19, 38]. These results indicated 
that XNT might be used to cure biofilm-related candidal 
infections and treat candidiasis.
On the other hand, XNT performed antifungal activity 
against planktonic fungal cells such as Malassezia spe-
cies [24] and opportunistic filamentous fungi [25]. Anti-
Malassezia activity of XNT was reported in M. furfur and 
M. pachydermatis [24]. XNT also inhibited the conidial 
germination of all six filamentous fungi species such as 
Aspergillus flavus, Aspergillus fumigatus, Aspergillus 
niger, Fusarium oxysporum, Rhizopus oryzae and Tricho-
phyton mentagrophtes based on NCCLS (M38-A) stand-
ard method. Its effect was comparable to amphotericin B 
[25].
Although antimicrobial mechanisms of XNT are not 
well understood, we believe that XNT may suppress 
nuclear factor kappaB (NF-kB) and mitogen-activated 
protein kinase (MAPK) induced by microbial infection. 
XNT has been demonstrated to inactivate both of them 
in skin cancer [26]. According to Wilken et  al., infec-
tious antigens could induce the activation of NF-kB [39]. 
For example, exposure of epithelial cells to C. albicans 
hyphae stimulates pro-inflammatory immune responses 
via NF-kB and MAPK pathways [40], which are also 
involved in the carcinogenesis [41, 42].
Based on epidemiologic studies, it has been estimated 
about 15  % of the worldwide cancer incidence is con-
siderably related with microbial infection [43]. Chronic 
infection of human papilloma virus in immunocompetent 
Table 1 Historical application of XNT
COX-2 cyclooxygensae-2, iNOS inducible nitric oxide synthase, TNF-α tumor necrosis factor-alpha, IL-6 interleukin-6, TPA 12-O-tetradecanoylphorbol-13-acetate, ODC 
ornithine decarboxylase, IkBα IkappaBalpha, H2O2 hydrogen peroxide, ROS reactive oxygen species, LDL low-density lipoprotein, FFA free fatty acid, TG triglyceride, 
IL-1β interleukin-1ß, CRP C-reactive protein, ADP adenosine diphosphate, JNK c-Jun N-terminal kinase, MAPK mitogen-activated protein kinases, NF-kB nuclear factor 
kappaB, AP-1 activator protein 1, GPT glutamate-pyruvate transaminase, GOT glutamate–oxaloacetate transaminase, pS2 trefoil factor 1, ERE estrogen responsive 
element, hERα human estrogen receptor-α
Pharmacoactivity Description References
Antimicrobial Antibacterial (Actinomyces viscosus, Porphyromona gingialis, Streptococcus mutans, Staphy-
lococcus aureus, methicillin-resistant S. aureus, Escherichia coli, Propionibacterium acnes), 
anticandidal (Candida albicans, C. glabrata, C. guilliermondii and C. parapsilosis), antifungal 
(Malassezia species, Aspergillus flavus, A. fumigatus, A. niger, Fusarium oxysporum, Rhizopus 
oryzae and Trichophyton mentagrophtes)
[15, 16, 19, 22–25]
Anti-inflammatory In vitro reduced COX-2, iNOS, TNF-α and IL-6 levels; in vivo counteracted the effect of 
 TPA-induced ODC, COX-2 and iNOS activation in mouse skin, and prevented IkBα  
degradation; blocked the neurogenic and inflammatory pain response in the formalin 
induced pain test in rats
[10, 17, 26, 27]
Antioxidant Suppressed H2O2-induced lipid peroxidation in rat brain homogenates, glutamate- 
induced neurotoxicity and ROS production; inhibited human LDL peroxidation
[5, 17]
Antihyperglycemic Reduced the levels of insulin, glucose, FFA, TG in serum; reduced the size of epididymal 
 fat pad and adipocyte; decreased the production of TNF-α, IL-6, IL-1β and CRP in adipose 
tissue, liver and muscle
[6]
Antihypertensive Calcium antagonistic activity in rat uterus and thoracic aorta [21, 28]
Antiplatelet Inhibited platelet aggregation stimulated by arachidonic acid, collagen and ADP [29]
Nephroprotective and hepatoprotective Attenuated JNKs phosphorylation involved in MAPK signaling; inactivated NF-kB, AP-1; 
downregulated COX-2 and iNOS, reduced blood GPT and GOT levels
[30–32]
Estrogenic and anti-estrogenic Upregulated pS2 and promoted EREs in MCF-7 cells; acted as partial antagonist hERα in 
T47D cells
[20, 33]
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hosts causes cervical carcinoma, whilst hepatitis B and 
C virus infection leads to hepatocellular carcinoma. 
Mirobes may also induce cancer incidence through 
opportunistic infection such as human herpes virus 
(HHV)-8 infection leading to Kaposi’s sarcoma [44–46]. 
In addition, gastric cancer secondary to Helicobacter 
pylori colonization or colon cancer may occur in certain 
people due to abnormal immune responses to microbes 
contributed by chronic inflammatory bowel disease pre-
cipitated by the intestinal microflora [44–46]. Since XNT 
has anticancer and antimicrobial properties, we sug-
gest that its antimicrobial mechanism studies should be 
conducted not only to develop XNT as a potent antimi-
crobial agent, but also provides new insight on the sup-
pression of microbes-induced cancer in the future.
Anti‑inflammatory properties
First in vitro anti-inflammatory report of XNT has been 
shown in lipopolysaccharide-activated mouse leukae-
mic monocyte macrophage cell RAW 264.7 [27]. XNT 
reduced cyclooxygenase-2 (COX-2) and inducible nitric 
oxide synthase (iNOS) activity by inhibiting the produc-
tion of prostaglandin E2 (PGE2) and nitric oxide (NO) 
respectively in lipopolysaccharide-activated mouse mac-
rophage cell RAW 264.7. These results indicated XNT 
may be a potent COX-2 and iNOS inhibitors [27], which 
is suggested by another anti-inflammatory assay of XNT 
performed in activated primary cultured microglial 
cells induced by lipopolysaccharide [17]. It was found to 
inhibit COX-2, iNOS, proinflammatory cytokine inter-
leukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in 
activated microglial cells. It is clear that XNT is capable 
to inhibit COX-2 and iNOS as consistent with several 
findings [26, 27, 30], whilst IL-6 and TNF-α as consistent 
with recent report [6].
Further in vivo anti-inflammatory studies of XNT have 
been conducted in 12-O-tetradecanoylphorbol-13-ac-
etate (TPA)-induced mouse acute inflammation model 
[26]. XNT has been reported to counteract the effect of 
TPA-induced ornithine decarboxylase (ODC), COX-2 
and iNOS activation in mouse skin. Since pro-inflam-
matory proteins COX-2 and iNOS are highly associated 
with cutaneous inflammation, cell proliferation and skin 
tumor promotion [26, 47], their suppression are impor-
tant to alleviate inflammation and prevent cancer [26, 
41, 42, 48]. The expression of COX-2 and iNOS might be 
regulated by transcription factor, NF-kB, as reported in 
cultured cell lines and TPA-induced cutaneous inflam-
mation in mouse skin [17, 26]. When nuclear transloca-
tion and DNA binding of NF-kB increase in response 
to external stimuli, NF-kB stimulates COX-2 and iNOS 
transcription [26, 48]. Thus, NF-kB plays a pivotal role in 
inflammation and tumorigenesis.
Another study postulated that XNT may exert anti-
inflammatory activity by blocking the neurogenic and 
inflammatory pain response in the formalin induced pain 
test in rats [10]. It may partly contribute to the analgesic 
effects or antinociceptive activity. However, the detailed 
mechanisms have not been worked out. From the inte-
gration of findings [10, 17, 26, 27], we summarize that 
anti-inflammatory mechanism of XNT involved inhibi-
tion of IL-6 and TNF-α, and suppression of COX-2 and 
iNOS expression via NF-kB pathway resulting PGE2 and 
NO reduction.
Antioxidant properties
Antioxidant properties of XNT contribute to its neu-
roprotective [17] and LDL oxidation inhibitory effects. 
XNT has been known to possess in  vitro antioxidant 
activity against murine hippocampal neuronal HT22 
cell line [17] and copper-mediated isolated human low-
density lipoprotein (LDL) oxidation [5]. In murine hip-
pocampal neuronal HT22 cell line, XNT reduced the free 
radical-mediated oxidative damage [17]. Its antioxidant 
properties exerted potent neuroprotective effects by sup-
pressing hydrogen peroxide (H2O2)-induced lipid per-
oxidation in rat brain homogenates, glutamate-induced 
neurotoxicity and reactive oxygen species (ROS) pro-
duction in HT22 cells. These results indicated that XNT 
could be a potent agent to treat Alzheimer’s disease and 
ROS associated neurological disease [17].
On the other hand, the inhibition of copper-catalysed 
LDL oxidation was evaluated employing thiobarbituric 
acid reactive substances (TBARSs) assay with human 
LDL as the oxidation substrate [5]. XNT strongly inhib-
ited human LDL peroxidation in a dose-dependent 
manner. The presence of phenolic hydroxyl group (ses-
quiterpene phenol) on the bisabolene skeleton of XNT, 
has most probably contributed to its strong antioxidant 
properties by chelating Cu2+. This in turns may sup-
press the initiation of LDL oxidation and generation of 
free radicals at the lipoprotein [5]. We suggest that XNT 
might be subjected to further investigation in cardiovas-
cular disorders because high LDL antioxidant activity 
could reduce the risk of heart attack. In vivo antioxidant 
assay could also be conducted in the future.
Antihyperglycemic properties
In vivo antihyperglycemic effects of XNT have been 
demonstrated in the high-fat diet (HFD)-induced obese 
mice [6]. XNT and C. xanthorrhiza extract with stand-
ardized XNT reduced the levels of insulin, glucose, free 
fatty acid (FFA), and triglyceride (TG) in their serum. 
XNT also reduced the size of epididymal fat pad and adi-
pocyte and decreased the production of inflammatory 
cytokines such as TNF-α, IL-6, interleukin-1ß (IL-1ß), 
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and C-reactive protein (CRP) in adipose tissue, liver and 
muscle of HFD-induced obese mice. Thus, XNT may 
prevent fatty liver disease (accumulation of liver fat) and 
chronic inflammation [6].
These results showed that XNT’s antihyperglycemic and 
anti-inflammatory activities may restrict and treat type 2 
diabetes, which is mainly caused by obesity-induced insulin 
resistance [6]. Insulin resistance is related to chronic low-
grade inflammation states such as increased proinflmma-
tory cytokine levels. The inflammation process is initiated 
by the activation of TNF-α, IL-6, IL-1ß and CRP, which 
are known to disrupt the transduction of insulin signalling 
causing insulin resistance [6]. Based on this study, we reveal 
that XNT could suppress HFD-induced metabolic disor-
ders including hyperglycemia, inflammation and hepatic 
injury by inhibiting fatty acid release from adipose tissue. 
We suggest that anti-obesity effects of XNT and its related 
mechanisms of action could be studied in the future.
Antihypertensive properties
XNT extracted from Iostephane heterophylla has shown 
potential antihypertensive activities [28]. A preliminary 
study demonstrated that XNT effectively inhibited pre-
contractions induced by calcium chloride, potassium 
chloride and noradrenaline in rat thoracic aorta rings. The 
vasorelaxation effect of XNT indicated that it may act as 
a calcium antagonist by reducing calcium influx into vas-
cular smooth muscle cells in rat aorta. In fact, its calcium 
antagonistic activity has been illustrated earlier in isolated 
rat uterine smooth muscle [21]. XNT attenuated the effect 
of rat uterus’ tonic contraction stimulated by calcium chlo-
ride, potassium and calcium channel agonist in a dose-
dependent manner. This might be due to the ability of XNT 
to block the voltage operated calcium influx in myome-
trial cells. According to Grossman and Messerli, calcium 
antagonists reduce blood pressure via vasodilation and 
decreased peripheral resistance [49]. Since calcium antago-
nists have been well established as basic antihypertensive 
drugs [50], we believe that XNT may have blood pressure-
lowering effect. However, detailed antihypertensive activi-
ties and mechanisms of XNT are yet to be elucidated.
Antiplatelet properties
In vitro antiplatelet activity of XNT (100 µg/mL) showed 
a strong inhibition towards platelet aggregation stimu-
lated by arachidonic acid (100 %), collagen (81.3 %) and 
adenosine diphosphate (ADP) (78.6  %) in human whole 
blood [29]. Although previous studies reported that the 
antiplatelet activity of curcumin was higher than XNT 
[29], the potential of XNT as an antiplatelet compound 
should not be neglected. We suggest that its antiplatelet 
mechanism requires further investigation.
Nephroprotective and hepatoprotective properties: 
cisplastin‑induced toxicity
Nephroprotective and hepatoprotective effects of XNT 
have been performed in male ICR mice treated with 
cisplatin [30–32]. Cisplatin is a potent chemotherapeu-
tic drug [31, 51], but the occurrence of nephrotoxicity 
has become the main limitation of using cisplatin-based 
chemotherapy [32, 52]. XNT exhibited nephroprotec-
tive effect by attenuating the increased specific gravity 
of kidney induced by cisplatin [32]. Cisplatin-induced 
kidney injury was reported as increased kidney weight, 
enhanced lipid peroxidation in kidney tissues, weakened 
filtration and excretion process of kidney, and subse-
quently increased blood urea nitrogen and serum creati-
nine levels. Pretreatment of XNT obviously restored the 
kidney weight to the base level and attenuated the ele-
vated levels of blood urea nitrogen and serum creatinine. 
Although DNA-binding activity of NF-kB and activator 
protein 1 (AP-1) did not contribute to the nephroprotec-
tive effect [32], the exact mechanism has not yet been 
identified.
High dose of cisplatin also induces hepatotoxicity [30, 
31]. Cisplatin increased DNA-binding activity of NF-kB 
but suppressed DNA-binding activity of AP-1. The func-
tion of NF-kB is to stimulate COX-2 and iNOS, which 
are associated with inflammation and toxicity. XNT 
pretreatment has been shown to abrogate these effects. 
XNT elicited hepatoprotective effects by reducing blood 
glutamate-pyruvate transaminase (GPT) and gluta-
mate–oxaloacetate transaminase (GOT) levels caused 
by cisplatin [30]. The mechanism involved XNT’s dose-
dependent attenuation of c-Jun N-terminal kinases 
(JNKs) phosphorylation in MAPK signaling, especially 
JNK1 [31]. This action may inhibit the transcription of 
COX-2, iNOS and transcription factor subunits (c-fos 
and p50). When XNT suppressed cisplatin-induced c-Fos 
protein expression, it may modulate the DNA-binding 
activity of NF-kB and AP-1, which in turns regulate 
COX-2 and iNOS expression. Mitochondrial apoptosis 
was excluded since the expression of both cytochrome 
c and caspase-9 was not changed [31]. Thus, it has been 
concluded that XNT minimized side effects of cisplatin-
induced hepatotoxicity by regulating the DNA-binding 
activities of transcription factors NF-kB and AP-1 [30] 
via blocking the phosphorylation of JNK(s) [31].
It was believed that XNT exerted better suppress-
ing effect towards cisplatin-induced nephrotoxicity [32] 
and hepatotoxicity than curcumin [30, 31]. At the same 
dose, curcumin was less effective in attenuating the 
elevated levels of blood urea nitrogen and serum creati-
nine [32]. XNT downregulated COX-2 and iNOS gene 
expression, but curcumin suppressed only COX-2 gene 
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[30]. Moreover, XNT abrogated the expression of NF-kB 
subunit, p50 and AP-1 subunit, c-fos, but not curcumin 
[31]. Combined with the findings of both nephroprotec-
tive and hepatoprotective effects, we assume that XNT 
could be clinically applied as a suppressant of toxicity for 
patients administrated with high dose cisplatin to pre-
vent kidney and liver damage.
Estrogenic and anti‑estrogenic properties
XNT has been known to possess estrogenic activity in 
estrogen receptor (ER)-positive MCF-7 cells during the 
state of hormone starvation [20, 33]. It has been reported 
that XNT treatment upregulated ER target gene expres-
sion, trefoil factor 1 (pS2) and promoted the interaction 
of ER-estrogen response elements (EREs) in MCF-7 cells. 
Since XNT has been proven to possess estrogenic activ-
ity in negligible estrogen level [20], we suggest that XNT 
could be further explored in the treatment of estrogen 
deficiency-induced menopausal symptoms, cardiovascu-
lar disease and osteoporosis.
In contrast, XNT was revealed as partial estrogen 
antagonist in T47D breast cancer cells [12]. In molecu-
lar docking simulation, the binding interaction between 
XNT and human estrogen receptor-α (hERα) indicated 
that XNT might be able to compete with estradiol. Both 
XNT and estradiol showed almost similar binding free-
energy. Also, a strong hydrophobic interaction found 
between XNT and hERα may be due to the presence of 
hydroxyl group (1-OH) and alkyl chains, leading to its 
potential as partial antagonist hERα. The postulation 
was confirmed by pharmacophore modeling, which 
identified that 1-OH and alkyl chain were two impor-
tant chemical features of XNT as partial antagonist 
hERα to strongly inhibit T47D cells. This molecular 
interaction with hERα also involved aromatic ring of 
XNT [12].
Based on the estrogenic [20, 33] and anti-estrogenic 
activities [12] reported, we suggest that XNT may act as a 
potent phytoestrogen with beneficial therapeutic poten-
tial. According to Tham et  al., the partial estrogenic/
anti-estrogenic behaviour is a common characteristic of 
phytoestrogens [53]. The estrogenic activity of phytoes-
trogens is 100 to 1000-fold weaker than 17β-estradiol, 
but its concentrations may be 100-fold higher than 
endogenous estrogens in the body [53]. Hence, we believe 
that abundant XNT molecules might act as competitive 
inhibitors of endogenous 17β-estradiol. XNT may block 
the actions of estradiol from binding to ERs of breast 
cancer cells, thus inhibiting tumor growth. Seeing that 
tumorigenesis of ER-positive luminal A cell lines (MCF-7 
and T47D) can be suppressed by anti-estrogen therapy 
[54], XNT could be developed as a potential anti-estro-
gen agent.
To further study the effects of XNT as phytoestrogens 
in vitro, estrogen should not be excluded in experimental 
condition because circulating estradiol exists at all stages 
of the life cycle [53]. XNT may exert both estrogenic and 
anti-estrogenic effects on human metabolism, depending 
on XNT and endogenous estrogens concentration, gen-
der and menopausal status.
Current status of XNT
In this review, other aspects of XNT have been consid-
ered including herb-drug interaction, toxicity studies 
and clinical studies. XNT showed synergistic antifungal 
effects with amphotericin B and ketoconazole in  vitro 
[55]. To date, only an in vivo toxicity study of XNT has 
been reported [56], whilst clinical study of XNT is not 
available so far. The details of XNT’s status have been 
described in the following sections.
Herb‑drug interaction
XNT‑amphotericin B or XNT‑ketoconazole
Rukayadi et  al. demonstrated that XNT-amphotericin 
B or XNT-ketoconazole showed in  vitro synergistic 
anticandidal effect against Candida albicans, Candida 
glabrata, Candida guilliermondii, Candida krusei, Can-
dida parapsilosis and Candida tropicalis [55]. Combined 
XNT with amphotericin B or ketoconazole inhibited 
the growth of all six Candida species and increased cell 
death by several logs within 4  h [55]. We propose that 
XNT could be added in the formulation of conventional 
antifungal agents such as amphotericin B or ketocona-
zole to increase drug efficacy. However, the risks of side 
effects still need to be investigated.
XNT‑pentobarbital
XNT at 50  mg/kg was found to prolong the pentobar-
bital-induced sleeping time in mice [56]. This was due 
to the interaction of XNT with cytochrome p450 to 
inhibit the metabolism of pentobarbital. Since XNT was 
reported to inhibit cytochrome p450 activity [56], we 
suggest that further studies could be conducted to eluci-
date its effects on hepatic drug metabolism.
Toxicity studies
According to Yamazaki et  al., a single oral administra-
tion of 500  mg/kg XNT showed no mortality in mice 
[56]. Since 1  mg of C. xanthorrhiza ethanolic extract 
contained 0.1238  mg of XNT [10], we estimate that up 
to 619  mg/kg XNT in 5  g/kg of this extract was safe to 
be administrated in mice. However, efficacy and safety 
dosage of XNT in targeted therapeutic areas are yet to be 
conducted in the future. Moreover, there are still lacking 
of studies on genotoxicity, carcinogenicity and reproduc-
tive toxicity of XNT.
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Clinical studies
To date, XNT data is unavailable in clinical pharmacol-
ogy and clinical efficacy studies [57]. Not every new 
candidate compound discovered is fully developed and 
marketed [58]. We reveal that some issues restraining 
the availability of clinical trials are funding limitations 
and difficulty getting approvals from Food and Drug 
Administration (FDA). Frohlich supported that one of 
the complexities surrounding clinical research is insuf-
ficient funding to conduct modern research [59]. Aside 
from funding, strict ethical and regulatory compliance 
enforced by our social structure [59] might prolong the 
new drug developmental process. The major concern 
of clinical research is the safety and efficacy of the can-
didate compound [58]. It normally takes 5–6 years for a 
candidate drug to be submitted in a new drug applica-
tion (NDA) to the FDA. Then, it required 6–10 months 
to complete the review of all the safety and efficacy data 
[58]. To overcome the delay of widespread access to new 
therapies, questionable data and ethical issues must be 
resolved. We suggest that necessary safety data, efficacy 
data and overall risk/benefit analysis are important key 
elements in successful sponsorship of XNT for future 
clinical studies.
Molecular and cellular mechanisms of XNT 
anticancer effects
XNT is a potential suppressor of carcinogenesis. See-
ing that several monophenolic groups possess cytotoxic 
activities, the cytotoxic effect of XNT may be contrib-
uted by its phenol group [13]. Its anticancer mechanisms 
are comprehensive and diverse by modulating different 
levels of cellular growth and apoptosis. The apoptotic 
morphology is usually characterized by DNA fragmenta-
tion, cell shrinkage, elongated lamellipodia and chroma-
tin condensation [7, 18, 60–62]. Taken together with the 
anticancer activities that have been reported [7, 12–14, 
18, 26, 41, 60–68], we suggest that the anticancer mecha-
nisms of XNT are closely associated to its antioxidative 
and anti-inflammatory activities, induction of apoptosis 
and cell cycle arrest.
XNT and antioxidative activity
XNT’s potent antioxidant and free radical-scavenging 
properties may exert chemopreventive effects on car-
cinogenesis. XNT was first reported to inhibit hepatic 
cytochrome p450 enzyme system by Yamazaki et  al. 
[56]. Cytochrome p450 plays an important role in the 
oxidation and detoxification of toxic compounds [39]. 
When it is exposed to toxin, oxidation occurs and sub-
sequently produces carcinogenic metabolites forming 
DNA adducts, which could initiate carcinogenesis [39]. 
Therefore, we deduce that XNT’s potent inhibitory effect 
on cytochrome p450 activity might suppress the initial 
stages of carcinogenesis by reducing ROS production in 
liver cells. Menon and Sudheer also presumed that mem-
brane lipids peroxidation mediated by free radical and 
oxidative damage of DNA and proteins might most likely 
link to cancer and neurodegenerative diseases [69]. It has 
been shown that XNT inhibited H2O2-induced lipid per-
oxidation in rat brain homogenates, glutamate-induced 
neurotoxicity, LDL peroxidation and ROS production [5, 
17]. In addition, ODC-induced reactive oxygen interme-
diates (ROIs) may also involve in the tumor promotion 
[69]. It is supported by a previous study where super-
oxide dismutase (SOD) and catalase suppressed ODC 
induction in murine mammary tumor cells [70]. Since 
XNT was able to suppress ODC in mouse skin cancer 
[26], we suggest that it may exert antipromotional activity 
via radical scavenging effect.
XNT and anti‑inflammatory activity
Inflammation has long been correlated with the pro-
gression of cancer [44–46, 69]. We believe that anti-
inflammatory activities of XNT may inhibit tumor 
promotion via the modulation of transcription fac-
tor NF-kB. Increased NF-kB activation is common in 
many cancers because it involves the cellular pathways 
leading to inflammation, angiogenesis, tumorigenesis 
and metastasis [39]. As NF-kB is stimulated by stress-
ful stimuli from cytokines (TNF-α and IL-1), multiple 
NF-kB regulated gene products (COX-2, iNOS, IL-6) 
might be upregulated [39].
As mentioned in Jantan et  al., XNT was capable to 
reduce TNF-α, IL-6, IL-1β production [5]. We infer that 
it can switch off NF-kB activation by cytokines, thus giv-
ing anti-inflammatory effects. This is evident by several 
studies [17, 26, 27, 30] that showed downregulation and 
reduction of COX-2 and iNOS. Indeed, both enzymes 
are important to mediate inflammatory processes [69]. 
Improper upregulation can cause certain human cancers 
and inflammatory disorders [69].
In mouse skin with TPA-induced acute inflammation 
(mouse ear edema) and 19  weeks TPA-induced tumor 
promotion in 7,12-dimethylbenz[a]anthracene (DMBA)-
initiated mouse skin, XNT suppressed cancer and 
inflammatory biomarkers including ODC, COX-2 and 
iNOS expression through MAPKs, NF-kB and or protein 
kinase B (Akt) [26]. XNT delayed or inhibited tumor for-
mation, and reversed the carcinogenic process at prema-
lignant stages [26]. Therefore, XNT’s anticancer activities 
may be associated with its anti-inflammatory property by 
inhibiting the NF-kB activity and subsequently the induc-
tion of COX-2 and iNOS.
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XNT and apoptosis induction
Induction of p53
Mitochondrial pathway apoptosis may be activated by 
p53-dependent or p53-independent pathway [71]. Sev-
eral studies have proven that XNT induces apoptosis via 
activation of p53-dependent mitochondrial pathway as 
reported in HepG2 liver cancer [7], HeLa cervical cancer 
[61] and MCF-7 breast cancer [60]. In HeLa cervical can-
cer cells, XNT upregulated p53 and Bax, but not affected 
anti-apoptotic protein, Bcl-2 [61]. It is assumed that p53 
may transcriptionally activate the pro-apoptotic Bax gene 
and/or repress anti-apoptotic Bcl-2 gene [72, 73]. Bax 
expression stimulates apoptosis, and the Bax gene prod-
uct attenuates the effect of Bcl-2 protein [61, 74]. Thus, 
increased p53 and Bax protein expression may restore 
the cervical cancer cells’ sensitivity towards apoptotic 
stimuli [61].
These findings are in contrast with those obtained by 
Cheah et al. and Handayani et al., where increased expres-
sion of p53 did not induce Bax expression, but reduced 
Bcl-2 level in MCF-7 breast cancer [60] and HepG2 liver 
cancer cells [7]. When Bcl-2 expression level is low and 
Bax expression level remains the same [75], homodimers 
of Bax will regularly be produced [7] causing an increase 
in Bax/Bcl-2 ratio. This increases the permeability of 
mitochondrial membrane and stimulates cytochrome 
c release from mitochondria, thus initiated apoptosis 
[7, 39]. We speculate that XNT induced apoptosis via 
p53-dependent mitochondrial pathway in certain cancer 
cells with different effects on Bax/Bcl-2 expression.
Caspase activation
To initiate caspase cascade, cytochrome c binds to apop-
totic protease activating factor-1 (Apaf-1) to form an apop-
tosome complex, which activates caspase-9 [39]. Caspase 
activation causes enzymatic proteolysis of cytoplasmic pro-
teins and DNA leading to cell death. The hallmarks of cas-
pase-dependent apoptosis as shown by XNT in cancer cells 
include increased mitochondrial membrane permeability 
and cytosolic release of cytochrome c (MDA-MB-231 inva-
sive breast cancer [63], HCT 116 colon cancer cells [65]), 
activation of caspase-3 and -9 (HepG2 [7], MDA-MB-231 
[63], HCT 116 cells [65]), reduced Bcl-XL expression 
(HepG2 [14], HCT116 cancer cells [65]), reduced Bcl-2 
expression (MCF-7 [60], HepG2 [14], Tca8113 tongue 
cancer cells [66]), truncation of Bid (HepG2 [14], HCT116 
cancer cells [65]) and cleavage of DNA repair enzyme poly-
(ADP-ribose) polymerase (PARP) (HepG2 [7], MCF-7 [60], 
MDA-MB-231 [63], HCT116 cancer cells [65]). Indeed, 
PARP is a target protein of caspase-3 [65] and important 
to hinder cellular depletion of ATP required for apoptosis 
event [63]. XNT also cleaved DNA fragmentation factor 
45/inhibitor of caspase-activated DNase (DFF45/ICAD) 
proteins in HepG2 cells [14]. These evidences suggest that 
the mode of XNT-induced cell death is mediated by the 
activation of caspase.
Induction of NAG‑1
Pro-apoptotic non-steroidal anti-inflammatory drug-
activated gene-1 (NAG-1) is a member of the transform-
ing growth factor-β (TGF-β) superfamily [65]. It has 
in vitro and in vivo pro-apoptotic and antitumor effects 
[76–78]. During the development of human colorectal 
cancer and neoplastic tumors, NAG-1 is notably inhib-
ited [65, 79, 80]. In HCT166 colon cancer study, XNT 
increased the expression and promoter activity of NAG-1 
[65]. NAG-1 could be stimulated in either a p53-depend-
ent [81] or p53-independent manner [82]. Although the 
effect of XNT on p53-induced NAG-1 expression was 
not investigated, enhanced NAG-1 expression by XNT 
promoted apoptosis in HCT116 cells. This is in agree-
ment with previous studies [76], where NAG-1 induced 
apoptosis in HCT-116 colon cancer cells. It was postu-
lated that NAG-1 gene regulation by XNT may involve 
inactivation of Akt/glycogen synthase kinase-3beta 
(GSK3β)/mammalian target of rapamycin (mTOR) sign-
aling [65]. Although Akt inhibition activated GSK3β and 
subsequently enhanced NAG-1 expression [79], the exact 
molecular mechanisms of Akt/GSK3β/mTOR signal-
ing on NAG-1-induced apoptosis are yet to be explored. 
Since NAG-1 is highly expressed in mature intestinal epi-
thelial cells [65], we believe that it is a reliable biomarker 
in colon cancer screening.
Regulation of MAPK pathway
Subfamily members of MAPK consist of extracellular 
signal-regulated kinase (ERK), JNK and p38 [41]. XNT’s 
modulation of MAPK pathway has been shown in oral 
cancer in vitro [67], lung cancer and skin cancer in vivo 
[41]. XNT significantly increased intracellular ROS pro-
duction and enhanced p38 and JNK phosphorylation in 
SCC-15 oral squamous cell carcinoma (OSCC) cells [67]. 
It was found to induce apoptosis by bypassing caspase 
cascade, where it cleaved PARP in the presence of caspase 
inhibitor. Since excessive accumulation of ROS in the 
cells can stimulate MAPK pathway, it is concluded that 
XNT induced caspase-independent apoptosis through 
ROS-mediated p38 MAPK and JNK activation in SCC-
15 OSCC cells. XNT also prevented DMBA-induced oral 
carcinogenesis in hamsters [67]. We infer that XNT not 
only has antioxidant effects, but may also exhibit pro-
oxidant activity to induce caspase-independent apoptosis 
during oxidative stress under pathological conditions.
In addition to oral cancer, XNT inhibited tumor nod-
ules in a spontaneous mouse lung metastasis model and 
mouse skin cancer by decreasing phosphorylated ERK 
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(pERK), JNK and p38 expression [26, 41]. XNT sup-
pressed the activation of ERK, JNK and p38 which were 
persistently enhanced during the development of mouse 
skin papillomagenesis [26]. In mouse lung metastasis, 
XNT counteracted the effect of threonine-protein kinase 
(Raf-1), which can trigger ERK activation [41]. It also 
downregulated matrix metalloproteinase-9 (MMP-9) 
and COX-2 involved in MAPK/ERK pathway, which is an 
important signal cascade to inhibit mouse lung metasta-
sis [41]. Taken together, these data provide evidence that 
XNT could exert antitumor effect through modulation of 
MAPK signalling pathway.
Inhibition of Akt/NF‑kB pathway
XNT inhibited Akt expression and TPA-induced NF-kB 
activation in mouse skin cancer [26]. Since Akt is a 
NF-kB upstream signal factor, Akt phosphorylation can 
activate IkappaB kinase (IKK) followed by NF-kB, which 
promotes cell survival pathway [83]. We believe that Akt 
inhibition by XNT could suppress NF-kB. Indeed, NF-kB 
is inactive when it forms a cytoplasmic complex with 
IkappaBalpha (IkBα) [69]. NF-kB becomes active when 
IkBα dissociates from NF-kB through rapid phosphoryla-
tion and subsequent proteasomes degradation [26]. This 
activation induces apoptosis resistance, thus promoting 
the proliferation and survival of cancer cells [84]. XNT 
attenuated these effects by hindering IkBα degradation 
in the cytosol and blocking NF-kB translocation into 
the nucleus [26]. This subsequently inhibited the nuclear 
accumulation and DNA binding of NF-kB [26]. Based on 
these findings, XNT could act as Akt and NF-kB inhibi-
tors to promote apoptosis.
In TE-1 and TE-4 esophageal squamous cancer cell 
lines, XNT suppressed the growth and decreased phos-
pho-Akt (p-Akt) expression [68]. He et al. indicated that 
reduced Akt or p-Akt expression may inhibit NF-kB 
activity and subsequently induce apoptosis [83]. This 
is because NF-kB is correlated with various steps in the 
progression of malignancy included expression of anti-
apoptotic protein Bcl-2 and Bcl-XL [39]. Thus, we infer 
that XNT exerted antiproliferative and antitumor activi-
ties in mouse skin cancer and esophageal cancer cells via 
inhibition of Akt/NF-kB signalling pathway.
XNT and cell cycle arrest
In addition to apoptosis induction, growth inhibitory 
pathways of XNT have been demonstrated in colon can-
cer, esophageal cancer and tongue cancer cells. Consid-
ering cyclin D1 proto-oncogene is ultimately important 
to modulate the transition of G1 to S phase in various 
cell types [85], XNT reduced cyclin D1 expression in 
HCT116 colon cancer [65], TE-1 and TE-4 esophageal 
squamous cancer cell lines [68].
In HCT116 colon cancer cells, XNT was found to 
inhibit the cell cycle in the G1 or G2/M phase by trig-
gering cyclin-dependent kinase inhibitors (CDKIs) such 
as p21 and p27 [65]. Cell cycle arrest in the G0/G1 and 
G2/M phase and increased sub-G1 peaks were closely 
associated with under-expression of cell cycle regulatory 
proteins such as cyclin A, B1, D1, cyclin-dependent kinase 
1 (CDK1), CDK2, CDK4 and proliferating cell nuclear 
antigen (PCNA), which is a biomarker for the cell prolif-
eration. Also, XNT stimulated G0/G1 and S + G2/M cell 
cycle arrest in human Tca8113 tongue cancer cell line 
[66]. To understand the molecular mechanisms by which 
XNT regulates cell cycle, extensive studies of its down-
stream signalling pathways will be necessary.
Anticancer properties
XNT was first known to possess anticancer proper-
ties when it was tested on Sarcoma 180 ascites in mice 
[64]. Sarcoma 180 ascites is a transplantable tumor [86]. 
Although the antitumor activity of XNT was found to be 
lower than α-curcumene [64], there is lack of mechanism 
studies on how XNT inhibited tumor growth of Sarcoma 
180 ascites.
On the other hand, antiproliferative activities of XNT 
have been demonstrated in many types of human breast 
cancer cells. These included MDA-MB-231 [18, 63], 
MDA-MB-453 [63], SK-BR-3 [63], MCF-7 [60], YMB-1 
[13] and T47D breast cancer cell lines [12, 63]. Among 
the six breast cancer cell lines, only the mechanism stud-
ies of XNT towards MDA-MB-231, MCF-7 and T47D 
cells have been reported. We recommend that future 
studies should be carried out on MDA-MB-453, SK-BR-3 
and YMB-1 cells to evaluate XNT’s capacity in breast 
cancer treatment. Furthermore, the anticancer activities 
of XNT have also been reported in colon cancer, cervical 
cancer, liver cancer, skin cancer, lung cancer, tongue can-
cer, oral cancer, esophageal cancer and ovarian cancer as 
summarized in Table 2.
XNT in cancer treatment
Although XNT has been researched extensively as an 
antiproliferative and antitumor agent, several issues 
should be considered for its safety and efficacy use. 
For example, different biological outcomes have been 
reported upon the treatment of combined XNT with 
other compounds or drugs in breast cancer and esoph-
ageal cancer. Also, cytoselectivity of XNT has been dis-
cussed in this section.
Breast cancer
XNT‑curcumin interaction
When combined XNT-curcumin was added to MDA-
MB-231 cells, the treatment reflected synergistic growth 
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inhibition as compared to XNT alone [18]. Increased 
apoptosis index such as alteration of membrane poten-
tial, DNA condensation, DNA fragmentation and cell 
shrinkage have been observed. Simultaneous treatment 
has proven greater cytotoxic effect than sequential treat-
ment with XNT and curcumin or vice versa [18]. There-
fore, we believe that combined XNT-curcumin could be 
examined further for future anticancer studies.
XNT‑tamoxifen interaction
Recent in  vitro and in  vivo studies of XNT-tamoxifen 
interaction conducted by Noomhorm and colleagues 
have contributed new information on breast cancer treat-
ment translational research. XNT was found to interact 
with tamoxifen increasing MCF-7 proliferative activity 
in vivo [33].
Tamoxifen is a common non-steroidal selec-
tive ER modulator used to treat pre-menopausal and 
post-menopausal women with receptor-positive, ER(+)/
progesterone receptor (PR)(+) breast cancers [33]. 
Although this hormonal therapy is recognized as a gold 
standard in hindering tumor recurrence of hormone-
responsive breast cancer, it always results both mild and 
serious unfavorable side effects. Co-treatment of XNT 
with tamoxifen in vitro demonstrated insignificant inter-
action, but the effects were remarkable in tumor-bear-
ing mice. In vitro study of XNT-tamoxifen interaction 
showed that there was no remarkable significant differ-
ence between XNT +  tamoxifen group and tamoxifen-
alone group in terms of cell number, luciferase activity, 
percentage S-phage cells and LC3-II expression [33].
However, in vivo results reflected that XNT interacted 
with tamoxifen causing increased tumor volumes, tumor 
size, tumor weight and protein expression of p27 (kip1) 
and p38 in the MCF-7 implanted athymic nude mice 
model [33]. Repeated dosing of XNT may accumulate its 
Table 2 Anticancer properties of XNT
PARP-1 poly-(ADP-ribose) polymerase-1, tBid truncation of bid, NAG-1 non-steroidal anti-inflammatory drug-activated gene-1, Akt protein kinase B, GSK3β 
glycogen synthase kinase-3beta, mTOR mammalian target of rapamycin, DFF45/ICAD DNA fragmentation factor 45/inhibitor of caspase-activated DNase, DMBA 
7,12-dimethylbenz[a]anthracene, ERK extracellular signal-regulated kinase, MMP matrix metalloproteinase, Raf-1 Raf-1 proto-oncogene serine/threonine-protein 
kinase, OSCC oral squamous cell carcinoma, p-Akt phospho-protein kinase B
Types of cancer Description References
Breast cancer (MDA-MB-231, MCF-7, T47D, YMB-1, MDA-MB-453 
and SK-BR-3 cells)
Induced mitochondrial-mediated apoptosis against MDA- 
MB-231 (↑ caspase-3, -9, cytochrome c and ↓ PARP-1)  
and MCF-7 cell apoptosis (↑ p53, ↓ Bcl-2 and PARP-1); acted as 
partial estrogen antagonist against T47D cell line
[12, 13, 18, 60, 63]
Colon cancer (HCT116 cells) Induced cell cycle arrest (G0/G1, G2/M phase and increased 
sub-G1 peaks); mitochondrial pathway apoptosis (↑ caspase-8, 
-9 and-3), tBID and ↓ Bcl-XL protein, cleavage of PARP; ↑ NAG-1 
may inactivate Akt pathway and subsequently suppressed 
GSK3β and mTOR
[65]
Cervical cancer (HeLa cells) Induced p53 and Bax-dependent apoptosis, but not Bcl-2 and E6 [61]
Liver cancer (HepG2 cells) Mitochondrial pathway apoptosis(↑ p53 ↓ Bcl-2 and Bcl-XL), but 
not Bax; caspase activation (caspase-3 and -9, not -7) involved 
tBid; cleavage of PARP and DFF45/ICAD proteins
[7, 14]
Skin cancer (HM3KO cells; TPA-induced tumor promotion in  
DMBA-initiated mouse skin)
Induced apoptosis in HM3KO cells; decreased tumor multiplicity 
and tumor incidence in DMBA-initiated mouse skin,  
suppressed ODC, COX-2 and iNOS expression through NF-kB 
(blocking IkBα degradation) and or Akt, inactivated ERK, p38,  
JNK and Akt
[26, 62]
Lung cancer (spontaneous mouse lung metastasis model) Downregulation of MMP and COX-2 in MAPK/ERK pathway 
(decreased COX-2, MMP-9 and phosphorylated ERK); attenuated 
expression of JNK and p38; counteracted the effect of Raf-1
[41]
Tongue cancer (Tca8113 cells) Induced cell cycle arrest in G0/G1 and S + G2/M phase; down-
regulated the protein expression of Bcl-2, but not Bax
[66]
Oral cancer (SCC-15 OSCC cells; DMBA-induced oral  
carcinogenesis in hamsters)
Caspase-independent apoptosis through ROS-mediated p38 
MAPK and JNK activation in SCC-15 OSCC cells; inhibited the 
tumors number in buccal pouches in hamsters treated with 
DMBA
[67]
Esophageal cancer (TE-1 and TE-4 cells) Reduced p-Akt and cyclin D1 expression; increased caspase-3 
expression
[68]
Sarcoma 180 ascites Lack of mechanism studies [64]
Ovarian cancer (CaOV-3 cells) Cytotoxic (lack of accessible information) [62]
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effect in stimulating cell proliferative activity of MCF-7 
cells in XNT  +  tamoxifen group compared to a single 
shot XNT treatment. Since p27(kip1) was upregulated 
in XNT +  tamoxifen group compared to the tamoxifen-
alone group, it was postulated that XNT may inactivate 
the functional properties of p27(kip1) resulting increased 
tumor growth. p27(kip1) is expelled from the nucleus 
rendering cell growth inhibition due to phosphorylation 
occurs at Ser of p27(kip 1). XNT also attenuated cytotoxic 
effects of tamoxifen against MCF-7 implanted nude mice, 
most probably via p38/MAPK signaling pathway [33].
Based on the cell type and stimuli, p38 MAPK exerts 
pro-apoptotic and anti-apoptotic effects [87]. A study 
conducted by Zhou and colleagues showed that suppres-
sion of p38 MAPK inhibited tumor growth in MCF-7 
xenografts [88], whilst Bacus and colleagues reported 
that activation of p38 MAPK was essential for MCF-7 
cells’ apoptosis [89]. It exerts the pro-apoptotic action by 
phosphorylating and translocating Bcl-2 family’s proteins, 
thus causing the mitochondrial release of cytochrome c 
[90]. Since p27(kip1) and p38 were over-expressed in this 
study, in vivo tumor-promoting effect of XNT-tamoxifen 
interaction may be probably due to the mutation occurred 
leading to protein p27(kip1) and p38 malfunction. Also, 
this herb-drug interaction may influence the output of 
p38/MAPK signaling pathway, where its upregulation 
promoted tumor growth in MCF-7 implanted nude mice. 
These findings supported that C. xanthorrhiza consisted 
mainly XNT should not be used in the long-term treat-
ment of tamoxifen treated breast cancer patients [33].
Esophageal cancer
In TE-1 and TE-4 esophageal squamous cancer cell lines, 
double combination of XNT and astaxanthine or triple 
combination of XNT, astaxanthine and α-tocopherol 
exerted synergistic apoptotic effects [68]. They reduced 
not only the expression of p-Akt and cyclin D1, but also 
exhibited a higher caspase-3 expression than XNT’s 
treatment alone in both esophageal cancer cells. On the 
other hand, previous studies indicated that combined 
astaxanthine and α-tocopherol did not exhibit any coop-
erative apoptosis, where they increased the expression of 
p-Akt and maintained caspase-3 levels compared to con-
trol [91]. In fact, astaxanthine or α-tocopherol treatment 
alone was effective against TE-1 and TE-4 esophageal 
cancer cells, but not their combination [91]. Thus, we 
postulate that the addition of XNT to astaxanthine and 
α-tocopherol may stimulate their antiproliferative prop-
erties giving synergistic effects.
Cytoselective and non‑cytoselective effects
Cytoselective toxicity of a bioactive compound is hardly 
defined. A bioactive compound may be cytotoxic in 
certain cells while inactive towards others. XNT has 
been considered as cytoselective when it was tested on 
HeLa cervical cancer cells as compared to non-malignant 
Chang’s Liver and MDBK cells [61]. EC50 value of XNT 
towards both cell lines was 4.7-fold and 2.8-fold higher 
than HeLa cells, respectively. Also, XNT was found to be 
more sensitive towards MCF-7 breast cancer cells than 
African green monkey kidney cells (COS-7) [20].
In another study [7], XNT was moderately cytoselec-
tive against Chang’s Liver cells but lowly cytoselective 
towards Vero kidney cells compared to HepG2 liver 
cancer cells. IC50 value of XNT in both normal cell 
lines was 2.1-fold and 1.6-fold higher than HepG2 cells, 
respectively. Also, XNT exhibited less than twofold 
lower growth inhibition and cytotoxicity in both MDBK 
and Vero cells as compared to MDA-MB-231 breast 
cancer cells [63]. Surprisingly, non-cytoselective activ-
ity of XNT has been reported in normal fibroblast cell 
line CCD1114sk as compared to malignant melanoma 
HM3KO cells [62]. These results indicated that cytoselec-
tive and non-cytoselective effects of XNT depend on cell 
types and biological variation.
Perspectives
Although in vivo studies reported that 500 mg/kg of XNT 
was not toxic to mice [56], we propose that in vivo phar-
macokinetic and pharmacodynamic studies are required 
to further evaluate its efficacy and safety profiles before 
going for clinical trials. This is because the process by 
which a compound is absorbed, distributed, metabolized 
and eliminated in  vivo are always far more complicated 
than in  vitro systems [92]. The primary goals of phar-
macokinetic studies are to enhance efficacy and reduce 
toxicity. In complex biological systems, the relationship 
between drug concentration at the site of action and its 
pharmacological response could be determined via phar-
macodynamic approaches [92]. We suggest that in  vivo 
rodent pharmacokinetic and pharmacodynamic studies 
of XNT should be conducted to ensure it has appropriate 
pharmacokinetic and pharmacodynamic properties to be 
investigated in clinical pharmacology and safety studies.
Since there is no information is available about geno-
toxicity, carcinogenicity and reproductive toxicity of 
XNT, future study on these areas would contribute 
important knowledge to the community and thus ben-
efit/risk ratio could be determined. In fact, understand-
ing the benefit/risk ratio is foremost important in drug 
prescription [93]. It is important to evaluate the tox-
icity of potential bioactive compound to improve the 
therapy effectiveness on humans and prevent devastat-
ing effects. As genotoxic effects are hardly detectable 
in human health, several toxicity tests could be used to 
assess the safety profile of XNT. In vitro and in  vivo 
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genotoxicity testing of pharmaceuticals are referred to 
International Conference on Harmonisation of Techni-
cal Requirements for Registration of Pharmaceuticals for 
Human Use (ICH)-harmonized guidance [94]. In vitro 
tests incorporate gene mutation in bacteria and cytoge-
netic evaluation of chromosomal damage and/or a test 
that detects gene mutation in mammalian cells. On the 
contrary, in vivo tests incorporate chromosomal damage 
using rodent hematopoietic cells and long-term assays 
for carcinogenicity in two different species such as mice 
and rats [94].
Conclusion
The preceding sections have provided the importance 
of XNT as a pharmaceutical agent in disease manage-
ment including cancer, infectious disease (bacteria, 
candida, fungi), inflammatory disease, metabolic syn-
drome (hyperglycemia and hypertension) and platelet 
disorder. It also has antioxidant, estrogenic and anti-
estrogenic, nephroprotective and hepatoprotective 
effects. To conclude, XNT is a very potent bioactive 
natural compound that could fulfil the current need for 
new drug discovery especially in anticancer therapeu-
tics. However, herb-drug interaction, pharmacokinetic 
and pharmacodynamic studies, possible genotoxicity, 
carcinogenicity, reproductive toxicity and clinical stud-
ies require further investigation in order to establish 
XNT as a standard drug.
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